April 2009
Volume 50, Issue 13
ARVO Annual Meeting Abstract  |   April 2009
The Effect of Prophylactic Use of IOP Lowering Medication on IOP Spikes After Intravitreal Injections
Author Affiliations & Notes
  • M. P. Frenkel
    Eye Research Foundation, Stuart, Florida
  • R. E. P. Frenkel
    Eye Research Foundation, Stuart, Florida
    Bascom Palmer Eye Institute, University of Miami, Florida
  • S. Haji
    Eye Research Foundation, Stuart, Florida
    East Florida Eye Institute, Stuart, Florida
  • Footnotes
    Commercial Relationships  M.P. Frenkel, None; R.E.P. Frenkel, None; S. Haji, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 5020. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. P. Frenkel, R. E. P. Frenkel, S. Haji; The Effect of Prophylactic Use of IOP Lowering Medication on IOP Spikes After Intravitreal Injections. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5020.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To determine if prophylactic use of IOP lowering medication is effective in reducing the IOP spikes after intravitreal injections of Pegaptanib (Macugen), Bevacizumab (Avastin), and Ranibizumab (Lucentis).

Methods: : 300 eyes with exudative AMD received intravitreal injections of one of three anti-VEGF medications: 100 eyes received Macugen (0.09 ml), 100 received Avastin (0.05ml), and 100 received Lucentis (0.05ml). IOP lowering medication, one hour prior to the injection, was used in 84 %, 56% and 68% times in eyes that received Macugen, Lucentis and Avastin respectively. IOP was measured prior to injection, within one minute after injection, and every 5-10 minutes until the pressure was reduced to a safe level. Vision was evaluated immediately following injection.

Results: : All three injections caused significant initial IOP spikes. 71.42% of Macugen, 46 % of Avastin and 56 % of Lucentis patients had a post-injection IOP spike greater than 40 mmHg. The IOP reduced to less than 30 mmHg in all three groups within 20 minutes.Prophylactic medication did not prevent post-injection IOP spikes. There was no statistically significant IOP reduction except at 1 interval in each Macugen and Avastin group.

Keywords: intraocular pressure • retina 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.